CORDLIFE Group : P8A 0%’s storage of cord blood units at its facility in Singapore “will not” be impacted by the indefinite suspension of accreditation by the Foundation for the Accreditation of Cellular Therapy, the consumer healthcare company said.

In a filing to the Singapore Exchange late on Thursday (Dec 7), Cordlife Group also said that the investigation by the Association for the Advancement of Blood & Biotherapies will not impact the storage of cord blood units at Cordlife Singapore.

The Association for the Advancement of Blood & Biotherapies had said in a statement that it is continuing to collect relevant information to help it decide on the accreditation status of the Cordlife facility.

These moves followed a six-month suspension notice from the Ministry of Health after seven of 22 cord-blood storage tanks at Cordlife were found to have been kept at temperatures above acceptable limits.

Cordlife Group had been accredited by the Foundation for the Accreditation of Cellular Therapy since November 2015, while it has had accreditation from the Association for the Advancement of Blood & Biotherapies for 18 years.

Cordlife shares closed S$0.015 lower at S$0.295 on Thursday, before the announcement.

GET BT IN YOUR INBOX DAILY

Start and end each day with the latest news stories and analyses delivered straight to your inbox.

Sign UpVIEW ALL